Susquehanna International Group, LLP Contrafect Corp Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.09 - $0.19 $8,949 - $18,893	99,437 Added 170.93%	157,612 $15,000
Q3 2022 Nov 14, 2022	BUY	$0.18 - $3.51 $10,471 - $204,194	58,175 New	58,175 $10,000
Q4 2021 Feb 14, 2022	BUY	$2.47 - $4.14 $104,103 - $174,488	42,147 Added 214.22%	61,822 $163,000
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $8,491 - $11,792	2,662 Added 15.65%	19,675 $80,000
Q1 2021 May 17, 2021	SELL	$4.46 - $6.68 $58,167 - $87,120	-13,042 Reduced 43.39%	17,013 $82,000
Q4 2020 Feb 16, 2021	BUY	$5.05 - $6.4 $42,243 - $53,536	8,365 Added 38.57%	30,055 $152,000
Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $109,534 - $151,613	21,690 New	21,690 $115,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.